Senologie - Zeitschrift für Mammadiagnostik und -therapie 2021; 18(01): 59-65
DOI: 10.1055/a-1069-1099
Übersicht

Implantate der weiblichen Brust – Teil 3: Malignome

Breast implants – Part 3: Malignant findings
Uwe Fischer
1   Diagnostisches Brustzentrum Göttingen BZG, Göttingen
,
Hafiez Said
2   Abteilung für Plastische und Rekonstruktive Chirurgie, Krankenhaus Neu Bethlehem, Göttingen
› Author Affiliations

Zusammenfassung

Hinsichtlich der bösartigen Tumoren muss bei Frauen mit Implantaten unterschieden werden zwischen dem extrem seltenen Krankheitsbild des anaplastisch großzelligen Lymphoms (ALCL) einerseits und dem herkömmlichen Brustkrebs andererseits. Während das brustimplantatinduzierte BIA-ALCL in aller Regel bereits anhand der nicht kontrastmittelgestützten Protokolle zu diagnostizieren ist, bedarf es für den Nachweis insbesondere kleinerer Mammakarzinome der Applikation eines Kontrastmittels. Es kommen dabei dynamische Protokolle zum Einsatz, die eine Visualisierung der Durchblutung der intramammären Strukturen ermöglichen. Bei der Verwendung qualitätsgesicherter, hoch aufgelöster Untersuchungen erweist sich die Mamma-MRT im Nachweis insbesondere des kleinen Mammakarzinoms allen anderen bildgebenden Verfahren überlegen. Im letzten Teil der dreiteiligen Präsentation werden das ALCL und kleine Mammakarzinome bei Frauen mit Implantaten unter besonderer Berücksichtigung der MRT präsentiert.

Abstract

There are two entities of malignoma in the breast of patients with breast implants: The extremely rare anaplastic large-cell lymphoma (ALCL) on the one hand, and the common breast carcinoma on the other hand. The breast implant-induced BIA – ALCL can be usually diagnosed on non-contrast enhanced MR imaging. For the detection of breast cancer – especially in an early stage – the application of contrast material is nessessary. Dynamic protocols are used to visualize the intramammary perfusion and the tumor neoangiogenesis in case of breast cancer. Using quality-assured examinations with a high spatial resolution, MRI of the breast has been shown to be the most sensitive tool in the detection of small breast cancer compared to other imaging modalities. In this last of three parts of a publication about MRI of breast implants, the authors describe the typical findings in patients with breast implants and ALCL or intramammary carcinomas.



Publication History

Article published online:
10 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Zentrum für Krebsregisterdaten. Brustkrebs (Mammakarzinom) (17.12.2019). Im Internet (Stand 16.08.2020): https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Brustkrebs/brustkrebs_node.html
  • 2 Keech Jr JA, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg 1997; 100: 554-555
  • 3 FDA. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) (23.10.2019). Im Internet (Stand 06.05.2020): https://www.fda.gov/medical-devices/breast-implants/questions-and-answers-about-breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alcl
  • 4 Doren EL, Miranda RN, Selber JC. et al. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg 2017; 139: 1042-1050
  • 5 Loch-Wilkinson A, Beath KJ, Knight RJW. et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk. Plast Reconstr Surg. 2017; 140: 645-654
  • 6 Messingschlager J, Mamarvar M. Brustimplantat-assoziiertes anaplastisches großzelliges Lymphom (BIA-ALCL) bei laktierender Patientin. Handchir Mikrochir Plast Chir 2019; 51: 1-2
  • 7 Kricheldorf J, Fallenberg EM, Solbach C. et al. Brustimplantat-assoziiertes Lymphom. Deutsches Ärzteblatt 2018; 38: 628-635
  • 8 Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J 2019; 39: S3-S13
  • 9 Clemens MW, Medeiros LJ, Butler CE. et al. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol 2016; 34: 160-168
  • 10 Shoenfeld Y, Agmon-Levin N. ‘ASIA’ – autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8
  • 11 De Boer M, Colaris M, van der Hulst RRWJ. et al. Is explantation of silicone breast implants useful in patients with complaints?. Immunol Res 2017; 65: 25-36
  • 12 Fuzzard SK, Teixeira R, Zinn R. A Review of the Literature on the Management of Silicone Implant Incompatibility Syndrome. Aesthetic Plast Surg 2019, Epub ahead of print
  • 13 Mann RM, Kuhl CK, Kinkel K. et al. Breast MRI: Guidelines from the European Society of Breast Imaging. Eur Radiol 2008; 18: 1307-1318
  • 14 Sinkus R, Siegmann K, Xydeas T. et al. MR elastography of breast lesions: Understanding the solid/liquid duality can improve the specificity of contrast-enhanced MR mammography. Magn Reson Med 2007; 58: 1135-1144
  • 15 McKnight AL, Kugel JL, Rossman PJ. et al. MR elastography of breast cancer: preliminary results. Am J Roentgenol 2002; 178: 1411-1417
  • 16 El Khouli RH, Jacobs MA, Mezban SD. et al. Diffusion-weighted Imaging Improves the Diagnostic Accuracy of Conventional 3.0-T Breast MR Imaging. Radiology 2010; 256: 64-73
  • 17 Guo Y, Cai YQ, Cai ZL. et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002; 16: 172-178
  • 18 Sinha S, Lucas-Quesada FA, Sinha U. et al. In vivo diffusion- weighted MRI of the breast: Potential for lesion characterization. J Magn Reson Imaging 2002; 15: 693-704
  • 19 Woodhams R, Matsunaga K, Iwabuchi K. et al. Diffusion-weighted imaging of malignant breast tumors: The usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer . J Comput Assist Tomogr 2005; 29: 644-649
  • 20 Fischer U, Korthauer A, Baum F. et al. Short first-pass MRI of the breast. Acta Radiol 2012; 53: 267-269
  • 21 Kuhl CK, Schrading S, Strobel K. et al. Abbreviated breast Magnetic Resonance Imaging (MRI): First postcontrast subtracted images and maximum-intensity projection- a novel approach to breast cancer screening with MRI. J Clin Onc 2014; 32: 2304-2310
  • 22 Fischer U. Atlas der MR-Mammografie. Hochauflösende Mamma-MRT. Stuttgart New York: Thieme; 2010 2. Auflage.
  • 23 American College of Radiology (ACR). Breast Imaging Reporting and Data System Atlas (BI‐RADS Atlas). Reston, Va: American College of Radiology; 2013
  • 24 Fischer U, von Heyden D, Vosshenrich R. et al. Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast. RÖFO 1993; 158: 287-292
  • 25 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF Registernummer: 032-045OL. http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom
  • 26 Fischer U, Baum F. Diagnostische Interventionen der Mamma. Stuttgart New York: Thieme; 2008
  • 27 Perlet C, Heywang-Kobrunner SH, Heinig A. et al. Magnetic Resonance-Guided, Vacuum-Assisted Breast Biopsy Results from a European Multicenter Study of 538 Lesions. Cancer 2006; 106: 982-990
  • 28 Fischer U, Schwethelm L, Baum F. et al. Effort, accuracy and histology of MR-guided vacuum biopsy of suspicious breast lesions – retrospective evaluation after 389 interventions. RÖFO 2009; 181: 774-781
  • 29 Schrading S, Strobel K, Keiulers A. et al. Safety and Efficacy of Magnetic Resonance-Guided Vacuum-Assisted Large-Volume Breast Biopsy (MR-Guided VALB). Invest Radiol 2017; 52: 186-193
  • 30 Kuhl CK, Weigel S, Schrading S. et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol 2010; 28: 1450-1457
  • 31 Sardanelli F, Podo F, Santoro F. et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): Final results. Invest Radiol 2011; 46: 94-105
  • 32 Riedl CC, Luft N, Bernhart C. et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 2015; 33: 1128-1135
  • 33 Fischer U, Luftner-Nagel S, Baum F. et al. The Value of Quality-Assured Magnetic Resonance Imaging of the Breast for the Early Detection of Breast Cancer in Asymptomatic Women. J Comput Assist Tomogr 2018; 42: 1-5
  • 34 Fischer U, Hollstein M, Luftner-Nagel S. et al. HR-MRI of the Breast at Intervals of Maximum 24 Months: Influence on Tumor Stage at the Time of Diagnosis. Int J Womens Health Wellness 2019; 5: 1-11
  • 35 Herborn CU, Marincek B, Erfmann D. et al. Breast augmentation and reconstructive surgery: MR imaging of implant rupture and malignancy. Eur Radiol 2002; 12: 2198-2206
  • 36 Topping A, George C, Wilson G. Appropriateness of MRI scanning in the detection of ruptured implants used for breast reconstruction. Br J Plast Surg 2003; 56: 186-189